Answers are grounded in this paper and cite their sources.
In Wilson disease (WD) severity of disease can vary widely, depending on time of diagnosis. Early treatment can prevent the development of symptoms in patients. In all patients, lifelong medical treatment is indicated. Currently available medical regimens include the copper chelators for example D-penicillamine (DPA) or trientine (TETA), acting to increase copper excretion and zinc salts (ZS), which reduce copper uptake. In this chapter, we discuss considerations regarding choice of drug and safety limitations.
No takes yet. Share an insight, caveat, or question.
Mohr et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: